Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147M
-
Number of holders
-
206
-
Total 13F shares, excl. options
-
84.8M
-
Shares change
-
+3.81M
-
Total reported value, excl. options
-
$4.28B
-
Value change
-
+$170M
-
Put/Call ratio
-
0.42
-
Number of buys
-
107
-
Number of sells
-
-93
-
Price
-
$50.45
Significant Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q3 2021
247 filings reported holding DNLI - Denali Therapeutics Inc. - COMMON STOCK as of Q3 2021.
Denali Therapeutics Inc. - COMMON STOCK (DNLI) has 206 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.8M shares
of 147M outstanding shares and own 57.61% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (15M shares), VANGUARD GROUP INC (8.17M shares), Crestline Management, LP (7.71M shares), BlackRock Inc. (7.56M shares), Temasek Holdings (Private) Ltd (5.37M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.76M shares), GILDER GAGNON HOWE & CO LLC (2.8M shares), STATE STREET CORP (2.8M shares), Flagship Pioneering Inc. (2.73M shares), and FMR LLC (2.68M shares).
This table shows the top 206 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.